Biotinylated Human FAP Protein, His,Avitag™, active dimer (MALS verified)
分子别名（Synonym）
FAP,FAPalpha,SIMP,Seprase,APCE
表达区间及表达系统（Source）
Biotinylated Human FAP Protein, His,Avitag (FAP-H82Q6) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Asp 760 (Accession # Q12884-1).
Predicted N-terminus: His | His
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 93.1 kDa. The protein migrates as 100-115 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介绍
成纤维细胞活化蛋白（FAP，亦称seprase）是一种II型跨膜丝氨酸蛋白酶。其细胞膜结合型与可溶型均具有脯氨酸后切割内肽酶活性，尤其偏好作用于Ala/Ser-Gly-Pro-Ser/Asn/Ala共有序列，同时可降解明胶和热变性I型胶原。该蛋白酶还表现出二肽基肽酶活性，优先水解Ala-Pro、Ile-Pro、Gly-Pro、Arg-Pro及Pro-Pro肽键。细胞膜结合型FAP通过与DPP4、PLAUR或整合素协同作用，参与细胞外基质（ECM）的胞周蛋白水解过程，进而促进细胞在ECM中的黏附、迁移和侵袭。在脑实质中，FAP通过降解蛋白聚糖brevican促进胶质瘤细胞侵袭。在黑色素细胞中，该蛋白通过不依赖丝氨酸蛋白酶活性的方式调控细胞增殖与存活，发挥肿瘤抑制作用。
关键字： FAP;FAP蛋白;FAP重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。